{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:26Z","timestamp":1753891766341,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01725","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:44:00Z","timestamp":1598503440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Chidamide and Cyclosporine for Refractory\/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up"],"prefix":"10.3389","volume":"10","author":[{"given":"Fang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxiong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017.","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/MD.0b013e3181573059","article-title":"Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients.","volume":"86","author":"Lachenal","year":"2007","journal-title":"Medicine (Baltimore)."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1200\/jop.18.00511","article-title":"Practical treatment approach for angioimmunoblastic T-Cell lymphoma.","volume":"15","author":"Moskowitz","year":"2019","journal-title":"J Oncol Practice."},{"key":"B6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archinte.1951.03810010058005","article-title":"Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology.","volume":"87","author":"Evans","year":"1951","journal-title":"AMA Arch Int Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ajh.25574","article-title":"Evans syndrome in adults\u2013incidence, prevalence, and survival in a nationwide cohort.","volume":"94","author":"Hansen","year":"2019","journal-title":"Am J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/jbm.S176144","article-title":"Evans syndrome: clinical perspectives, biological insights and treatment modalities.","volume":"9","author":"Jaime-P\u00e9rez","year":"2018","journal-title":"J Blood Med."},{"key":"B9","first-page":"899","article-title":"Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.","volume":"6","author":"Alizadeh","year":"2008","journal-title":"Clin Adv Hematol Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12185-018-02587-6","article-title":"A case of AITL complicated by EBV-positive B cell and monoclonal plasma cell proliferation and effectively treated with lenalidomide.","volume":"109","author":"Kishimoto","year":"2019","journal-title":"Int J Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/ejh.13239","article-title":"Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma.","volume":"103","author":"Crickx","year":"2019","journal-title":"Eur J Haematol."},{"key":"B15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.V79.4.942.942","article-title":"Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSB) F1.","volume":"79","author":"Mizutani","year":"1992","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/mph.0000000000000897","article-title":"Natural history, pathogenesis, and treatment of evans syndrome in children.","volume":"39","author":"Mantadakis","year":"2017","journal-title":"J Pediatr Hematol Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immune globulin for hematologic conditions.","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus Med Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine.","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology."},{"key":"B19","first-page":"622","article-title":"Glucocorticoid-resistant Evans\u2019 syndrome successfully controlled with low-dose cyclosporine.","volume":"49","author":"Jani\u0107","year":"2011","journal-title":"Int J Clin Pharmacol Therapeut."},{"key":"B20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1442-200x.1999.01004.x","article-title":"Treatment of refractory Evans\u2019 syndrome with cyclosporine and prednisone.","volume":"41","author":"Uc\u0328ar","year":"1999","journal-title":"Pediatr Int Off J Jap Pediatr Soc."},{"key":"B21","first-page":"156","article-title":"Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone.","volume":"16","author":"Rackoff","year":"1994","journal-title":"Am J Pediatr Hematol Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.","volume":"48","author":"Advani","year":"2007","journal-title":"Leukemia Lymphoma."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000330950","article-title":"Successful treatment of chemotherapy-refractory angioimmunoblastic T cell lymphoma with cyclosporin A.","volume":"127","author":"Kobayashi","year":"2012","journal-title":"Acta Haematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.6002\/ect.2013.0265","article-title":"Cyclosporine treatment of angioimmunoblastic T-cell lymphoma relapsed after an autologous hematopoietic stem cell transplant.","volume":"13","author":"Wang","year":"2015","journal-title":"Exp Clin Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2019.1652590","article-title":"Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review.","volume":"12","author":"Ohmoto","year":"2019","journal-title":"Expert Rev Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.biopha.2016.08.023","article-title":"A novel histone deacetylase inhibitor Chidamide induces G0\/G1 arrest and apoptosis in myelodysplastic syndromes.","volume":"83","author":"Liu","year":"2016","journal-title":"Biomed Pharmacother Biomed Pharmacother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"77586","DOI":"10.18632\/oncotarget.20659","article-title":"Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12944","article-title":"Effective remission of chidamide on treatment of advanced mycosis fungoides: an unusual case report.","volume":"32","author":"Che","year":"2019","journal-title":"Dermatol Ther."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009611","article-title":"Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: a case report and literature review.","volume":"97","author":"Jin","year":"2018","journal-title":"Medicine (Baltimore)."},{"key":"B31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-and T-cell lymphomas.","volume":"54","author":"Marquard","year":"2009","journal-title":"Histopathology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:44:05Z","timestamp":1598503445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":32,"alternative-id":["10.3389\/fonc.2020.01725"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01725","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"article-number":"1725"}}